Vaccine hesitancy about the HPV vaccine among French young women and their parents: a telephone survey.
Attitude to health
HPV vaccination
Vaccine hesitancy
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
01 04 2023
01 04 2023
Historique:
received:
31
12
2021
accepted:
28
02
2023
medline:
4
4
2023
entrez:
3
4
2023
pubmed:
4
4
2023
Statut:
epublish
Résumé
The human papillomavirus (HPV) vaccine reduces the burden of cervical and other cancers. In numerous countries, a slow uptakeof this vaccine persists, calling for a better understanding of the structural factors leading to vaccine acceptation. We aimed to assess the attitudes toward HPV vaccination among its intended public to explore its specific characteristics. A random cross-sectional telephone survey of the French general population provided data from a sample of 2426 respondents of the target public: the parents of young women and the young women aged 15-25 themselves. We applied cluster analysis to identify contrasting attitudinal profiles, and logistic regressions with a model averaging method to investigate and rank the factors associated with these profiles. A third of the respondents had never heard of HPV. However, most of the respondents who had heard of it agreed that it is a severe (93.8%) and frequent (65.1%) infection. Overall, 72.3% of them considered the HPV vaccine to be effective, but 54% had concerns about its side effects. We identified four contrasting profiles based on their perceptions of this vaccine: informed supporters, objectors, uninformed supporters, and those who were uncertain. In multivariate analysis, these attitudinal clusters were the strongest predictors of HPV vaccine uptake, followed by attitudes toward vaccination in general. Tailored information campaigns and programs should address the specific and contrasted concerns about HPV vaccination of both young women and of their parents.
Sections du résumé
BACKGROUND
The human papillomavirus (HPV) vaccine reduces the burden of cervical and other cancers. In numerous countries, a slow uptakeof this vaccine persists, calling for a better understanding of the structural factors leading to vaccine acceptation. We aimed to assess the attitudes toward HPV vaccination among its intended public to explore its specific characteristics.
METHODS
A random cross-sectional telephone survey of the French general population provided data from a sample of 2426 respondents of the target public: the parents of young women and the young women aged 15-25 themselves. We applied cluster analysis to identify contrasting attitudinal profiles, and logistic regressions with a model averaging method to investigate and rank the factors associated with these profiles.
RESULTS
A third of the respondents had never heard of HPV. However, most of the respondents who had heard of it agreed that it is a severe (93.8%) and frequent (65.1%) infection. Overall, 72.3% of them considered the HPV vaccine to be effective, but 54% had concerns about its side effects. We identified four contrasting profiles based on their perceptions of this vaccine: informed supporters, objectors, uninformed supporters, and those who were uncertain. In multivariate analysis, these attitudinal clusters were the strongest predictors of HPV vaccine uptake, followed by attitudes toward vaccination in general.
CONCLUSIONS
Tailored information campaigns and programs should address the specific and contrasted concerns about HPV vaccination of both young women and of their parents.
Identifiants
pubmed: 37005583
doi: 10.1186/s12889-023-15334-2
pii: 10.1186/s12889-023-15334-2
pmc: PMC10066945
doi:
Substances chimiques
Papillomavirus Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
628Informations de copyright
© 2023. The Author(s).
Références
Soc Sci Med. 2014 May;109:10-8
pubmed: 24681239
BMC Med Educ. 2022 Apr 20;22(1):299
pubmed: 35443661
Nat Immunol. 2019 Oct;20(10):1257-1259
pubmed: 31477920
Vaccine. 2021 Jan 15;39(3):521-528
pubmed: 33328141
Public Health Rev. 2020 May 14;41:10
pubmed: 32435520
Z Gesundh Wiss. 2022 Jan 07;:1-25
pubmed: 35018277
Vaccine. 2021 Sep 24;39(40):5741-5747
pubmed: 34483023
Hum Vaccin Immunother. 2013 Aug;9(8):1763-73
pubmed: 23584253
Health Educ Behav. 2018 Feb;45(1):68-76
pubmed: 28595454
Pediatrics. 2006 May;117(5):1486-93
pubmed: 16651301
Syst Biol. 2004 Oct;53(5):793-808
pubmed: 15545256
Sex Transm Infect. 2016 Sep;92(6):474-9
pubmed: 26792088
Vaccine. 2016 Feb 3;34(6):762-8
pubmed: 26752063
Brain Behav Immun. 2021 May;94:41-50
pubmed: 33713824
Pediatrics. 2008 Oct;122(4):718-25
pubmed: 18829793
PLoS Curr. 2015 Feb 25;7:
pubmed: 25789201
J Cereb Blood Flow Metab. 2003 Apr;23(4):490-8
pubmed: 12679726
Vaccine. 2003 Jan 30;21(7-8):593-5
pubmed: 12531323
Vaccine. 2011 Jan 29;29(5):890-5
pubmed: 20056186
Hum Vaccin Immunother. 2019;15(7-8):1615-1627
pubmed: 30633623
Soc Sci Med. 2020 Nov;265:113414
pubmed: 33038683
Arch Dis Child. 2018 Aug;103(8):740-746
pubmed: 29222179
Hum Vaccin Immunother. 2020 Aug 2;16(8):1835-1840
pubmed: 31860406
Ann Behav Med. 2012 Oct;44(2):171-80
pubmed: 22547155
Sociol Health Illn. 2019 Jul;41(6):1192-1206
pubmed: 30972804
Best Pract Res Clin Obstet Gynaecol. 2018 Feb;47:14-26
pubmed: 29037457
Expert Rev Vaccines. 2017 Nov;16(11):1107-1118
pubmed: 28914112
PLoS One. 2018 Sep 20;13(9):e0202564
pubmed: 30235216
Best Pract Res Clin Obstet Gynaecol. 2018 Feb;47:42-58
pubmed: 28986092
Vaccine. 2020 Jan 29;38(5):1040-1047
pubmed: 31787415
Wkly Epidemiol Rec. ;92(19):241-68
pubmed: 28530369
Papillomavirus Res. 2017 Jun;3:142-148
pubmed: 28720448
Euro Surveill. 2018 Apr;23(17):
pubmed: 29717693
Best Pract Res Clin Obstet Gynaecol. 2018 Feb;47:2-13
pubmed: 28964706
Mem Inst Oswaldo Cruz. 2018;113(8):e180063
pubmed: 29846395
MMWR Morb Mortal Wkly Rep. 2019 Aug 23;68(33):724-728
pubmed: 31437140
Med J Aust. 2016 Mar 21;204(5):184-184e1
pubmed: 26985843
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Prev Med. 2021 Mar;144:106399
pubmed: 33388322
J Adolesc Health. 2008 Sep;43(3):239-45
pubmed: 18710678